EUVIMEDOpdag EUVIMED
Vergleichsstudie

Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia

Emily T Graves, Lynn Wardlow iD, Stella Ogake, Jose A Bazan, Kelci Coe iD, Kaitlyn Kuntz, Jessica L Elefritz iD

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf024 ↗

At a glance

Vergleichsstudie in Journal of Antimicrobial Chemotherapy, 2025. Written by Emily T Graves and 6 co-authors. Institution: Department of Pharmacy, The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210, USA. Major MEDLINE topics: Stenotrophomonas maltophilia, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Bacterial Agents, Gram-Negative Bacterial Infections. Cited 12 times so far (Crossref); 16 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

To compare the rate of clinical cure and adverse effects in patients receiving definitive treatment with trimethoprim-sulfamethoxazole versus minocycline monotherapy for Stenotrophomonas maltophilia pneumonia.

Methods

A single-centre, retrospective cohort study of patients with S. maltophilia pneumonia admitted 1 March 2018—30 September 2023 was conducted comparing treatment with trimethoprim-sulfamethoxazole versus minocycline monotherapy. The primary outcome was the rate of clinical cure, defined as meeting two of the three prespecified criteria for a period of 48 hours while on definitive therapy: normalization of white blood cell count, absence of fever and hypothermia and decreased oxygen support. Secondary outcomes evaluated included time to clinical cure, infection-related and in-hospital mortality, pneumonia recurrence and incidence of adverse effects, which was a composite of acute kidney injury (AKI), hyperkalaemia and thrombocytopenia.

Results

Of 93 patients included, 48 received trimethoprim-sulfamethoxazole and 45 received minocycline. There was no difference in the primary outcome of clinical cure between the trimethoprim-sulfamethoxazole and minocycline groups (72.9% versus 66.7%, P = 0.51). S. maltophilia pneumonia recurrence was more common in the minocycline group compared to the trimethoprim-sulfamethoxazole group (35.6% versus 10.4%, P = 0.006). In-hospital mortality was higher in the trimethoprim-sulfamethoxazole group although there was no difference in infection-related in-hospital mortality (6.3% versus 2.3%, P = 0.62). The incidence of AKI, hyperkalaemia and thrombocytopenia did not differ between groups.

Conclusion

There was no difference in clinical cure rate for S. maltophilia pneumonia treatment between trimethoprim-sulfamethoxazole and minocycline monotherapy although higher rates of recurrent pneumonia were observed in patients treated with minocycline. Rates of adverse effects were similar between groups.

Subjects

MeSH terms (MEDLINE)

Stenotrophomonas maltophiliaTrimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsGram-Negative Bacterial InfectionsMinocyclinePneumonia, BacterialHumansMaleRetrospective StudiesFemaleAgedMiddle AgedTreatment OutcomeAged, 80 and overAdult

Substances

Trimethoprim, Sulfamethoxazole Drug CombinationAnti-Bacterial AgentsMinocycline

Authors and institutions

  • Department of Pharmacy, The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210, USA.
  • Division of Pulmonary Diseases, Critical Care Medicine, and Sleep, The Ohio State University College of Medicine, 370 W 9th Ave, Columbus, OH 43210, USA.
  • Division of Infectious Diseases, The Ohio State University College of Medicine, 370 W 9th Ave, Columbus, OH 43210, USA.
  • Division of Infectious Diseases, The Ohio State University College of Medicine Address: 370 W 9th Ave, Columbus, OH 43210, USA.
  • The Ohio State University, College of Pharmacy, 500 W 12th Ave, Columbus, OH 43210, USA.

ORCID profiles: Lynn Wardlow, Kelci Coe, Jessica L Elefritz

Cite

APA

Graves, E. T., Wardlow, L., Ogake, S., Bazan, J. A., Coe, K., Kuntz, K., & Elefritz, J. L. (2025). Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf024

Vancouver

Graves ET, Wardlow L, Ogake S, Bazan JA, Coe K, Kuntz K, et al. Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf024

BibTeX
@article{Graves2025,
  author = {Graves, Emily T and Wardlow, Lynn and Ogake, Stella and Bazan, Jose A and Coe, Kelci and Kuntz, Kaitlyn and Elefritz, Jessica L},
  title = {Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf024}
}
Start for free →